{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:41:53Z","timestamp":1790649713716,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gynecologic Oncology Group Statistical Office","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}]},{"name":"NRG Oncology","award":["1 U10 CA180822"],"award-info":[{"award-number":["1 U10 CA180822"]}]},{"name":"NRG Operations","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ygyno.2018.06.017","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T13:20:53Z","timestamp":1530624053000},"page":"466-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology\/Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"150","author":[{"given":"Robert A.","family":"Burger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Debernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2018.06.017_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"issue":"7463","key":"10.1016\/j.ygyno.2018.06.017_bb0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ygyno.2018.06.017_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13000-017-0605-8","article-title":"TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer","volume":"12","author":"Zhang","year":"2017","journal-title":"Diagn. Pathol."},{"issue":"17","key":"10.1016\/j.ygyno.2018.06.017_bb0020","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2018.06.017_bb0025","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ygyno.2018.06.017_bb0030","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology\/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2018.06.017_bb0035","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ygyno.2018.06.017_bb0040","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.06.017_bb0045","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ccr.2005.09.016","article-title":"Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed","volume":"8","author":"Kerbel","year":"2005","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.ygyno.2018.06.017_bb0050","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ygyno.2018.06.017_bb0055","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","article-title":"Mechanisms of TGF-beta signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ygyno.2018.06.017_bb0060","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1161\/01.RES.0000095246.40391.3B","article-title":"Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling","volume":"93","author":"Seki","year":"2003","journal-title":"Circ. Res."},{"issue":"Pt 10","key":"10.1016\/j.ygyno.2018.06.017_bb0065","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1242\/jcs.061556","article-title":"BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo","volume":"123","author":"Suzuki","year":"2010","journal-title":"J. Cell Sci."},{"issue":"2","key":"10.1016\/j.ygyno.2018.06.017_bb0070","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/1535-7163.MCT-09-0650","article-title":"ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth","volume":"9","author":"Mitchell","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.ygyno.2018.06.017_bb0075","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1078-0432.CCR-13-1840","article-title":"Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer","volume":"20","author":"Bendell","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2018.06.017_bb0080","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2014.03.571","article-title":"A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study","volume":"133","author":"Alvarez","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.06.017_bb0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a gynecologic oncology group study","volume":"123","author":"Behbakht","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2018.06.017_bb0090","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.06.017_bb0095","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ygyno.2012.03.023","article-title":"A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a gynecologic oncology group study","volume":"125","author":"Gold","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.06.017_bb0100","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.ygyno.2013.12.018","article-title":"A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a gynecologic oncology group study","volume":"132","author":"Martin","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.06.017_bb0105","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ygyno.2009.10.071","article-title":"A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study","volume":"116","author":"Rocereto","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.06.017_bb0110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ygyno.2012.06.009","article-title":"Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study","volume":"127","author":"Schilder","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.06.017_bb0115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2013.01.006","article-title":"A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a gynecologic oncology group study","volume":"129","author":"Schilder","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.06.017_bb0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2011.02.013","article-title":"A gynecologic oncology group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies","volume":"121","author":"Usha","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.06.017_bb0130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2015.04.006","article-title":"Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG oncology\/gynecologic oncology group study 0229N","volume":"138","author":"Makker","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2018.06.017_bb0135","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1002\/cncr.30317","article-title":"A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"122","author":"Jimeno","year":"2016","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.ygyno.2018.06.017_bb0140","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1158\/1078-0432.CCR-16-2395","article-title":"The DART study: results from the dose-escalation and expansion cohorts evaluating the combination of Dalantercept plus Axitinib in advanced renal cell carcinoma","volume":"23","author":"Voss","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2018.06.017_bb0145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clin. Trials"},{"key":"10.1016\/j.ygyno.2018.06.017_bb0150","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818309995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818309995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T22:30:15Z","timestamp":1720391415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818309995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0090825818309995"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.06.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology\/Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}